Market Report -- In Play (HLCS)

November 10, 2009 7:17 AM ET

Article tools

Stocks mentioned in this article: Helicos BioSciences Corp (HLCS) Stock Quote, Chart, News, Add to Watchlist
Related topics: Movers

Helicos BioSciences decided to disengage from discussions involving a potential sale of the Company at the current time Co announced in its third quarter Form 10-Q filing that, as previously disclosed, it engaged Thomas Weisel Partners to assist with its evaluation and execution of strategic alternatives. Based on the Company's improving standalone prospects and its current market valuation, the Board of Directors has decided to disengage from discussions involving a potential sale of the Company at the current time. The Company continues to work with TWP as a financial advisor in connection with its long term financing strategy. Chief Executive Officer Ron Lowy commented: "We have had very positive feedback from our initial customers. In addition, we are seeing a growing number of novel discoveries resulting from the Helicos(R) Genetic Analysis System's unique capabilities and have seen an increased interest in clinical applications for which the Helicos system is uniquely suited. Not only do we have a significant lead in single molecule sequencing, but we also have established a first-mover advantage in diagnostics and biomarker discovery using single molecule sequencing technology. Our recent strategic dialogues have confirmed this."

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.